Overview

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This research is being done to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in people with microsatellite stable pancreatic cancer. The names of the study interventions involved in this study are: - Ipilimumab - Nivolumab - Radiation Therapy
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Bristol-Myers Squibb
Treatments:
Ipilimumab
Nivolumab